(Q41150961)

27 September 2017

title

The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation (English)

1 reference

27 September 2017

Sumeyye Calp-Inal

1

1 reference

27 September 2017

Maria Ajaimy

2

1 reference

27 September 2017

Michal L Melamed

3

1 reference

27 September 2017

Christina Savchik

4

1 reference

27 September 2017

Peter Masiakos

5

1 reference

27 September 2017

Adriana Colovai

6

1 reference

27 September 2017

Enver Akalin

7

1 reference

27 September 2017

language of work or name

English

0 references

publication date

4 November 2015

1 reference

27 September 2017

1 reference

27 September 2017

volume

89

1 reference

27 September 2017

issue

1

1 reference

27 September 2017

page(s)

209-216

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2015.275

27 September 2017

exact match

0 references

cites work

Diagnosis and management of antibody-mediated rejection: current status and novel approaches

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Desensitization protocols and their outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Pretransplant Donor-Specific HLA Class-I and -II Antibodies Are Associated With an Increased Risk for Kidney Graft Failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Sensitization after kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Complement-binding anti-HLA antibodies and kidney-allograft survival

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Determinants of C1q binding in the single antigen bead assay

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Therapeutic inhibition of the early phase of complement activation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Molecular diagnosis of antibody-mediated rejection in human kidney transplants

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Summary of FDA antibody-mediated rejection workshop

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Banff 07 classification of renal allograft pathology: updates and future directions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2015.275

7 January 2021

Identifiers

DOI

10.1038/KI.2015.275

1 reference

release_hcgcczfd6zauhey3662msxt6ym

27 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hcgcczfd6zauhey3662msxt6ym

24 November 2022

mapped directly with Wikidata item

1 reference